ReviewClinical ophthalmology (Auckland, N.Z.)2020
Boston Type 1 Keratoprosthesis: Updated Perspectives.
Review in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Revolutionizing vision using corneal 3D printing.Trends in biotechnology · 2026Review
- Prosthetic Corneal Surgery: A Narrative Review of Current Keratoprostheses and the Future Prospects of New Biomaterials.Bioengineering (Basel, Switzerland) · 2026Review
- Seeing through collagen: integrative pro-regenerative corneal implants for clearer future.NPJ Regenerative medicine · 2026Review
- Osteo-odonto-keratoprosthesis: a surgical procedure for treating advanced corneal diseases.The Saudi dental journal · 2026Review
- Progressive Insights into 3D Bioprinting for Corneal Tissue Restoration.Advanced healthcare materials · 2026Review
- A historical view of the development of corneal transplantation: from penetrating keratoplasty to selective transplantation of the finest corneal layers.Wiener medizinische Wochenschrift (1946) · 2025Review
- Risk factors for early and late retinal detachment after boston type I keratoprosthesis surgery.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Synergistic Dual Ag/Cu Ion Implantation to Enhance Antimicrobial Defense on Boston Keratoprosthesis.Biomaterials research · 2025Article
- Mooren's ulcer: a multifactorial autoimmune peripheral ulcerative keratitis and current treatment protocols.Frontiers in medicine · 2025Review
- Clinical Outcomes and Early Postoperative Complications in Boston Type I Keratoprosthesis Implantation: A Retrospective Study.Journal of clinical medicine · 2024Article
- Advancements in Hydrogels for Corneal Healing and Tissue Engineering.Gels (Basel, Switzerland) · 2024Review
- Pseudochamber-Protected Keratoplasty (PPK) with a New Inter-Corneal Surgical Device Implant Technique in High-Risk Cases.Journal of clinical medicine · 2024Article
- Replace or Regenerate? Diverse Approaches to Biomaterials for Treating Corneal Lesions.Biomimetics (Basel, Switzerland) · 2024Review
- Towards Precision Ophthalmology: The Role of 3D Printing and Bioprinting in Oculoplastic Surgery, Retinal, Corneal, and Glaucoma Treatment.Biomimetics (Basel, Switzerland) · 2024Review
- Outcomes of Boston Keratoprosthesis Type I Implantation in Poland: A Retrospective Study on 118 Patients.Journal of clinical medicine · 2024Article
- Antibacterial and cytocompatible silver coating for titanium Boston Keratoprosthesis.Frontiers in bioengineering and biotechnology · 2024Article
- Biocompatibility and Transplantation Efficacy of the C-Clear Artificial Cornea in a Rabbit Chemical Burn Model.Bioengineering (Basel, Switzerland) · 2023Article
- Application of biomaterials and nanotechnology in corneal tissue engineering.The Journal of international medical research · 2023Review
- The first-in-human implantation of the CorNeat keratoprosthesis.Eye (London, England) · 2023Article
- Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implantation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.